protein

Recombinant Human Cyclin-Dependent Kinase Inhibitor 2A TAT

MBS142831

1 mg

2665 USD

Recombinant Protein

Recombinant Human Cyclin-Dependent Kinase Inhibitor 2A TAT

Cyclin-Dependent Kinase Inhibitor 2A

p16-INK4a Human, TAT; Cyclin-Dependent Kinase Inhibitor 2A Human Recombinant, TAT; Cyclin-dependent kinase 4 inhibitor A; CDK4I; p16-INK4; p16-INK4a; p16INK4A; CDKN-2A; CDKN2; Multiple tumor suppressor 1; MTS1; CMM2; MLM; TP16; p16(INK4); p19

cyclin-dependent kinase inhibitor 2A isoform p16INK4a; Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; cyclin-dependent kinase inhibitor 2A; CDK4 inhibitor p16-INK4; CDKN2A; cell cycle negative regulator beta; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); multiple tumor suppressor 1; cyclin-dependent kinase inhibitor 2A; Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A

p16-INK4a-TAT

CDKN2A; CDKN2A; ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A; CDKN2; MTS1; CDK4I; MTS-1; p16-INK4; p16INK4A

CD2A1_HUMAN

E Coli

156

EPAAGSSMEP SADWLATAAA RGRVEEVRAL LEAGALPNAP NSYGRRPIQV MMMGSARVAE LLLLHGAEPN CADPATLTRP VHDAAREGFL DTLVVLHRAG ARLDVRDAWG RLPVDLAEEL GHRDVARYLR AAAGGTRGSN HARIDAAEGP SDIPDGGYGR KKRRQRRR.

Greater than 95.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.

Lyophilized from a 0.2 um filtered concentrated solution in 1xPBS, pH 7.4. Sterile Filtered White lyophilized (freeze-dried) powder.

Lyophilized p16-INK4a although stable at room temperature for 3 weeks, should be stored desiccated below -18 degree C. Upon reconstitution p16-INK4a should be stored at 4 degree C between 2-7 days and for future use below -18 degree C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.

Solubility: It is recommended to reconstitute the lyophilized p16-INK4a in sterile 18M?-cm H2O not less than 100 ug/ml, which can then be further diluted to other aqueous solutions.

PROTEIN KINASES; Enzymes; Cyclin-Dependent Kinase

Description: p16-INK4a Human Recombinant is a single, non-glycosylated, polypeptide chain produced in E Coli, containing a total of 168 amino acids, which includes the 156 residues of full-length p16-INK4a and a 13-residue C-terminal TAT peptide (GGYGRKKRRQRRR), having a total Mw of 18kDa. p16-INK4a is purified by proprietary chromatographic techniques. Introduction: Cyclin-dependent kinase inhibitors (CDKIs) are proteins that bind to and inhibit the activity of CDKs. Two major classes of CDK inhibitors have been identified. The p16 family (p15, p16, p18 and p19) binds to and inhibits the activities of CDK4 and CDK6. The p21 family (p21, p27, p28 and p57) can bind to broad range of CDK-cyclin complexes and inhibit their activities. CDKIs are capable of suppressing growth, and several lines of evidence strongly suggest that at least some CDKIs may be tumor suppressor proteins.

4502749

NP_000068.1

NM_000077.4

P42771

8,731 Da

Apoptosis Pathway 198797!!Apoptosis Modulation And Signaling Pathway 198822!!Bladder Cancer Pathway 83115!!Bladder Cancer Pathway 527!!Cell Cycle Pathway 530733!!Cell Cycle, Mitotic Pathway 105765!!Cell Cycle Pathway 198811!!Cell Cycle Pathway 83054!!Cell Cycle Pathway 463!!Cellular Senescence Pathway 905991

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]

1 mg

2665 USD